Viewing Study NCT00394251


Ignite Creation Date: 2025-12-24 @ 11:57 PM
Ignite Modification Date: 2026-04-16 @ 7:50 AM
Study NCT ID: NCT00394251
Status: COMPLETED
Last Update Posted: 2019-11-25
First Post: 2006-10-30
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer
Sponsor: Celgene
Organization: